Pemphigus autoimmunity: Hypotheses and realities

References

• Grando SA, Bystryn JC, Chernyavsky AI, Frusic-Zlotkin M, Gniadecki R, Lotti R, Milner Y, Pittelkow MR, Pincelli C. Apoptolysis: A novel mechanism of skin blistering in pemphigus vulgaris linking the apoptotic pathways to basal cell shrinkage and suprabasal acantholysis. Exp Dermatol. 2009; 18:764–770.
   PubMed Web of Science ®Google Scholar
• Carson PJ, Hameed A, Ahmed AR. Influence of treatment on the clinical course of Pemphigus vulgaris. J Am Acad Dermatol. 1996; 34:645–652.
   PubMed Web of Science ®Google Scholar
• Ahmed AR, Moy R. Death in Pemphigus. J Am Acad Dermatol. 1982; 7:221–228.
   PubMed Web of Science ®Google Scholar
• Rosenberg FR, Sanders S, Nelson CT. Pemphigus: A 20-year review of 107 patients treated with corticosteroids. Arch Dermatol. 1976; 112:962–970.
   PubMed Web of Science ®Google Scholar
• Anhalt GJ, Kim SC, Stanley JR, Korman NJ, Jabs DA, Kory M, Izumi H3rd, Ratrie H, Mutasim D, Ariss-Abdo L, Labib RS. Paraneoplastic Pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med. 1990; 323:1729–1735.
   PubMed Web of Science ®Google Scholar
• Kaplan RP, Callen JP. Pemphigus associated diseases and induced Pemphigus. Clin Dermatol. 1983; 1:42–71.
   PubMedGoogle Scholar
• Armin A, Nadimi H, Robinson J. Pemphigus vulgaris and malignancy. Int J Oral Surg. 1985; 14:376–380.
   PubMedGoogle Scholar
• Younus J, Ahmed AR. The relationship of Pemphigus to neoplasia. J Am Acad Dermatol. 1990; 23:498–502.
   PubMed Web of Science ®Google Scholar
• Ohyama M, Amagai M, Hashimoto T, Nousari HC, Anhalt GJ, Nishikawa T. Clinical phenotype and anti-desmoglein autoantibody profile in paraneoplastic Pemphigus. J Am Acad Dermatol. 2001; 44:593–598.
   PubMed Web of Science ®Google Scholar
• Nguyen VT, Ndoye A, Bassler KD, Shultz LD, Shields MC, Ruben BS, Webber RJ, Pittelkow MR, Lynch PJ, Grando SA. Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome: A reappraisal of paraneoplastic Pemphigus. Arch Dermatol. 2001; 137:193–206.
   PubMedGoogle Scholar
• Nousari HC, Deterding R, Wojtczack H, Aho S, Uitto J, Hashimoto T, Anhalt GJ. The mechanism of respiratory failure in paraneoplastic Pemphigus. N Engl J Med. 1999; 340:1406–1410.
   PubMed Web of Science ®Google Scholar
• Czernik A, Camilleri M, Pittelkow MR, Grando SA. Paraneoplastic autoimmune multiorgan syndrome: Twenty years after. Int J Dermatol. 2011; 50 8: 905–914.
   PubMed Web of Science ®Google Scholar
• Billet SE, Grando SA, Pittelkow MR. Paraneoplastic autoimmune multiorgan syndrome: Review of the literature and support for a cytotoxic role in pathogenesis. Autoimmunity. 2006; 39:617–630.
   PubMed Web of Science ®Google Scholar
• Beutner E, Jordon R. Demonstration of skin antibodies in sera of Pemphigus vulgaris patients by indirect immunofluorescent staining. Proc Soc Exp Biol Med. 1964; 117:505–510.
   PubMed Web of Science ®Google Scholar
• Beutner EH, Prigenzi LS, Hale W, Leme Cde A, Bier OG. Immunofluorescent studies of autoantibodies to intercellular areas of epithelia in Brazilian Pemphigus foliaceus. Proc Soc Exp Biol Med. 1968; 127:81–86.
   PubMed Web of Science ®Google Scholar
• Stanley JR, Yaar M, Hawley-Nelson P, Katz SI. Pemphigus antibodies identify a cell surface glycoprotein synthesized by human and mouse keratinocytes. J Clin Invest. 1982; 70:281–288.
   PubMed Web of Science ®Google Scholar
• Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel epithelial cadherin in Pemphigus vulgaris, a disease of cell adhesion. Cell. 1991; 67:869–877.
   PubMed Web of Science ®Google Scholar
• Nguyen VT, Ndoye A, Shultz LD, Pittelkow MR, Grando SA. Antibodies against keratinocyte antigens other than desmogleins 1 and 3 can induce Pemphigus vulgaris-like lesions. J Clin Invest. 2000; 106:1467–1479.
   PubMed Web of Science ®Google Scholar
• Ablin RJ, Bronson P, Beutner EH. Immunochemical characterization of epithelial antigen(s) reactive with Pemphigus-like antibodies of rabbit and human Pemphigus autoantibodies. J Hyg Epidemiol Microbiol Immunol. 1969; 13:321–329.
   PubMedGoogle Scholar
• Shu SY, Beutner EH. Isolation and characterization of antigens reactive with Pemphigus antibodies. J Invest Dermatol. 1973; 61:270–276.
   PubMed Web of Science ®Google Scholar
• Miyagawa S, Hojo T, Ishii H, Yoshioka J, Sakamoto K. Isolation and characterization of soluble epidermal antigens reactive with Pemphigus antibodies. Acta Derm Venereol. 1977; 57:7–13.
   PubMed Web of Science ®Google Scholar
• Calvanico NJ, Swartz SJ. A non-desmoglein component of bovine epidermis reactive with Pemphigus foliaceus sera. J Autoimmun. 1994; 7:231–242.
   PubMed Web of Science ®Google Scholar
• Calvanico NJ, Martins CR, Diaz LA. Characterization of Pemphigus foliaceus antigen from human epidermis. J Invest Dermatol. 1991; 96:815–821.
   PubMedGoogle Scholar
• Diaz LA, Patel H, Calvanico NJ. Isolation of Pemphigus antigen from human saliva. J Immunol. 1980; 124:760–765.
   PubMed Web of Science ®Google Scholar
• Diaz LA, Sampaio SA, Martins CR, Rivitti EA, Macca ML, Roscoe JT, . An autoantibody in Pemphigus serum, specific for the 59 kD keratin, selectively binds the surface of keratinocytes: Evidence for an extracellular keratin domain. J Invest Dermatol. 1987; 89:287–295.
   PubMed Web of Science ®Google Scholar
• Murahata RI, Ahmed AR. Partial purification and characterization of Pemphigus-like antigens in urine. Arch Derm Res. 1983; 275:118–123.
   PubMed Web of Science ®Google Scholar
• Peterson LL, Wuepper KD. Isolation and purification of a Pemphigus vulgaris antigen from human epidermis. J Clin Invest. 1984; 73:1113–1120.
   PubMed Web of Science ®Google Scholar
• Acosta E, Ivanyi L. Identification of Pemphigus-like antigens expressed by SCaBER cells. Br J Dermatol. 1985; 112:157–164.
   PubMed Web of Science ®Google Scholar
• Stanley JR, Koulu L, Thivolet C. Distinction between epidermal antigens binding Pemphigus vulgaris and Pemphigus foliaceus autoantibodies. J Clin Invest. 1984; 74:313–320.
   PubMed Web of Science ®Google Scholar
• Gilbert D, Joly P, Jouen F, Thibout A, Delpech A, Thomine E, Lauret P, Tron F. Production of a human monoclonal anti-epithelial cell surface antibody derived from a patient with Pemphigus vulgaris. J Autoimmun. 1992; 5:173–182.
   PubMed Web of Science ®Google Scholar
• Lyubimov H, Goldshmit D, Michel B, Oron Y, Milner Y. Pemphigus—identifying the autoantigen and its possible induction of epidermal acantholysis via Ca2+ signalling. Israel J Med Sci. 1995; 31:42–48.
   PubMedGoogle Scholar
• Kiss M, Husz S, Molnar K, Dobozy A. Identification of different circulating autoantibodies in patients with bullous Pemphigoid and Pemphigus vulgaris by means of immunoblotting. Acta Microbiol Immunol Hung. 1996; 43:115–123.
   PubMedGoogle Scholar
• Ding X, Aoki V, Mascaro JMJr, Lopez-Swiderski A, Diaz LA, Fairley JA. Mucosal and mucocutaneous (generalized) Pemphigus vulgaris show distinct autoantibody profiles. J Invest Dermatol. 1997; 109:592–596.
   PubMed Web of Science ®Google Scholar
• Joly P, Gilbert D, Thomine E, Zitouni M, Ghohestani R, Delpech A, Lauret P, Tron F. Identification of a new antibody population directed against a desmosomal plaque antigen in Pemphigus vulgaris and Pemphigus foliaceus. J Invest Dermatol. 1997; 108:469–475.
   PubMed Web of Science ®Google Scholar
• Eyre RW, Stanley JR. Identification of Pemphigus vulgaris antigen extracted from normal human epidermis and comparison with Pemphigus foliaceus antigen. J Clin Invest. 1988; 81:807–812.
   PubMed Web of Science ®Google Scholar
• Nguyen VT, Ndoye A, Grando SA. Novel human α9 acetylcholine receptor regulating keratinocyte adhesion is targeted by Pemphigus vulgaris autoimmunity. Am J Pathol. 2000; 157:1377–1391.
   PubMed Web of Science ®Google Scholar
• Marchenko S, Chernyavsky AI, Arredondo J, Gindi V, Grando SA. Antimitochondrial autoantibodies in Pemphigus vulgaris: A missing link in disease pathophysiology. J Biol Chem. 2010; 285:3695–3704.
   PubMed Web of Science ®Google Scholar
• Cirillo N, Gombos F, Lanza A. Pemphigus vulgaris immunoglobulin G can recognize a 130 000 MW antigen other than desmoglein 3 on peripheral blood mononuclear cell surface. Immunology. 2007; 121:377–382.
   PubMed Web of Science ®Google Scholar
• Mejri K, Abida O, Kallel-Sellami M, Haddouk S, Laadhar L, Zarraa I, Ben Ayed M, Zitouni M, Mokni M, Lahmar H, Fezaa B, Turki H, Tron F, Masmoudi H, Makni S. Spectrum of autoantibodies other than anti-desmoglein in Pemphigus patients. J Eur Acad Dermatol Venereol. 2010; 25 7: 774–781.
   PubMed Web of Science ®Google Scholar
• Stanley JR, Koulu L, Klaus-Kovtun V, Steinberg MS. A monoclonal antibody to the desmosomal glycoprotein desmoglein I binds the same polypeptide as human autoantibodies in Pemphigus foliaceus. J Immunol. 1986; 136:1227–1230.
   PubMed Web of Science ®Google Scholar
• Kurzen H, Brenner S. Significance of autoimmunity to non-desmoglein targets in Pemphigus. Autoimmunity. 2006; 39:549–556.
   PubMed Web of Science ®Google Scholar
• Mahoney MG, Wang Z, Rothenberger K, Koch PJ, Amagai M, Stanley JR. Explanations for the clinical and microscopic localization of lesions in Pemphigus foliaceus and vulgaris. J Clin Invest. 1999; 103:461–468.
   PubMed Web of Science ®Google Scholar
• Chen J, Den Z, Koch PJ. Loss of desmocollin 3 in mice leads to epidermal blistering. J Cell Sci. 2008; 121:2844–2849.
   PubMed Web of Science ®Google Scholar
• Amagai M, Karpati S, Klaus-Kovtun V, Udey MC, Stanley JR. Extracellular domain of Pemphigus vulgaris antigen (Desmoglein 3) mediates weak homophilic adhesion. J Invest Dermatol. 1994; 102:402–408.
   PubMed Web of Science ®Google Scholar
• Green KJ, Simpson CL. Desmosomes: New perspectives on a classic. J Invest Dermatol. 2007; 127:2499–2515.
   PubMed Web of Science ®Google Scholar
• Desai BV, Harmon RM, Green KJ. Desmosomes at a glance. J Cell Sci. 2009; 122:4401–4407.
   PubMed Web of Science ®Google Scholar
• Chernyavsky AI, Arredondo J, Kitajima Y, Sato-Nagai M, Grando SA. Desmoglein versus non-desmoglein signaling in Pemphigus acantholysis: Characterization of novel signaling pathways downstream of Pemphigus vulgaris antigens. J Biol Chem. 2007; 282:13804–13812.
   PubMed Web of Science ®Google Scholar
• Nguyen VT, Lee TX, Ndoye A, Shultz LD, Pittelkow MR, Dahl MV, Lynch PJ, Grando SA. The pathophysiological significance of non-desmoglein targets of Pemphigus autoimmunity. Pemphigus vulgaris and foliaceus patients develop antibodies against keratinocyte cholinergic receptors. Arch Dermatol. 1998; 134:971–980.
   PubMedGoogle Scholar
• Kalantari-Dehaghi M, Molina DM, Farhadieh M, Morrow WJ, Liang X, Felgner PL, Grando SA. New targets of Pemphigus vulgaris antibodies identified by protein array technology. Exp Dermatol. 2011; 20:154–156.
   PubMed Web of Science ®Google Scholar
• Kalantari-Dehaghi M, Anhalt G, Camilleri M, Leiferman KM, Marchenko S, Pittelkow M, Zone JJ, Grando SA. Pemphigus vulgaris antibodies target PERP and several other keratinocyte membrane and mitochondrial proteins. J Invest Dermatol. 2011; 131 Suppl. 1: S11.
   PubMedGoogle Scholar
• Ihrie RA, Marques MR, Nguyen BT, Horner JS, Papazoglu C, Bronson RT, Mills AA, Attardi LD. Perp is a p63-regulated gene essential for epithelial integrity. Cell. 2005; 120:843–856.
   PubMed Web of Science ®Google Scholar
• Bektas M, Rubenstein DS. Perp and Pemphigus: A disease of desmosome destabilization. J Invest Dermatol. 2009; 129:1606–1608.
   PubMed Web of Science ®Google Scholar
• Ihrie RA, Reczek E, Horner JS, Khachatrian L, Sage J, Jacks T, Attardi LD. Perp is a mediator of p53-dependent apoptosis in diverse cell types. Curr Biol. 2003; 13:1985–1990.
   PubMed Web of Science ®Google Scholar
• Davies L, Gray D, Spiller D, White MR, Damato B, Grierson I, Paraoan L. P53 apoptosis mediator PERP: Localization, function and caspase activation in uveal melanoma. J Cell Mol Med. 2009; 13:1995–2007.
   PubMed Web of Science ®Google Scholar
• Grando SA. Cholinergic control of epidermal cohesion in norm and pathology. Exp Dermatol. 2006; 15:265–282.
   PubMed Web of Science ®Google Scholar
• Grando SA, Kurzen H. 2009. Cholinergic control of keratinocyte cohesion. In: Cirillo N, Lanza A, Gombo F. editors. Pathophysiology of the desmosome104 Research Signpost, Managing Editor Dr. S.G. Pandalai, Trivandrum, Kerala, India.
   Google Scholar
• Grando SA, George PM, Dahl MV, Conti-Tronconi BM. Antibody against keratinocyte nicotinic acetylcholine receptor in patient with coexistent Pemphigus foliaceus, myasthenia gravis and thymoma. J Invest Dermatol. 1994; 102:609 (Abstr.).
   Web of Science ®Google Scholar
• Craft J, Fatenejad S. Self antigens and epitope spreading in systemic autoimmunity. Arthritis Rheum. 1997; 40:1374–1382.
   PubMedGoogle Scholar
• Lindstrom J. Autoimmune diseases involving nicotinic receptors. J Neurobiol. 2002; 53:656–665.
   PubMedGoogle Scholar
• Kalantari M, Molina DM, Farhadieh M, Vigil A, Morrow WJ, Liang X, Felgner PL, Grando SA. Partial evaluation of Pemphigus vulgaris autoantibody profile using the protein array technology. J Invest Dermatol. 2010; 130 Suppl. 1: S21.
   Google Scholar
• Patel M, Furstenberg G, Hazelton J, Tiagi S, Seiffert-Sinha K, Haab BB, Robinson WH, Sinha AA. Development of protein microarrays to investigate autoantibody profiles in Pemphigus vul-garis (abstr. #111). J Invest Dermatol. 2010; 130 Suppl. 1: s19.
   Google Scholar
• Nguyen VT, Ndoye A, Grando SA. Pemphigus vulgaris antibody identifies pemphaxin—a novel keratinocyte annexin-like molecule binding acetylcholine. J Biol Chem. 2000; 275:29466–29476.
   PubMed Web of Science ®Google Scholar
• Bastian BC, Nuss B, Romisch J, Kraus M, Brocker EB. Autoantibodies to annexins: A diagnostic marker for cutaneous disorders?. J Dermatol Sci. 1994; 8:194–202.
   PubMedGoogle Scholar
• Abreu Velez AM, Yi H, Gao W, Smoller BR, Grossniklaus HE, Howard MS. Antibodies to pilosebaceous units along their neurovascular supply routes in a new variant of endemic Pemphigus foliaceus in Colombia, South America. Eur J Dermatol. 2011; 21 3: 371–375.
   PubMed Web of Science ®Google Scholar
• Echigo T, Hasegawa M, Inaoki M, Yamazaki M, Sato S, Takehara K. Antiphospholipid antibodies in patients with autoimmune blistering disease. J Am Acad Dermatol. 2007; 57:397–400.
   PubMed Web of Science ®Google Scholar
• Blondin DA, Zhang Z, Shideler KK, Hou H, Fritzler MJ, Mydlarski PR. Prevalence of non-organ-specific autoantibodies in patients with Pemphigus vulgaris. J Cutan Med Surg. 2009; 13:82–87.
   PubMed Web of Science ®Google Scholar
• Amagai M, Karpati S, Prussick R, Klaus-Kovtun V, Stanley JR. Autoantibodies against the amino-terminal cadherin-like binding domain of Pemphigus vulgaris antigen are pathogenic. J Clin Invest. 1992; 90:919–926.
   PubMed Web of Science ®Google Scholar
• Amagai M, Hashimoto T, Shimizu N, Nishikawa T. Absorption of pathogenic autoantibodies by the extracellular domain of Pemphigus vulgaris antigen (Dsg3) produced by baculovirus. J Clin Invest. 1994; 94:59–67.
   PubMed Web of Science ®Google Scholar
• Amagai M, Hashimoto T, Green KJ, Shimizu N, Nishikawa T. Antigen-specific immunoadsorption of pathogenic autoantibodies in Pemphigus foliaceus. J Invest Dermatol. 1995; 104:895–901.
   PubMed Web of Science ®Google Scholar
• Amagai M, Nishikawa T, Nousari HC, Anhalt GJ, Hashimoto T. Antibodies against desmoglein 3 (Pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic Pemphigus and cause acantholysis in vivo in neonatal mice. J Clin Invest. 1998; 102:775–782.
   PubMed Web of Science ®Google Scholar
• Moller NP. Fc-mediated immune precipitation. I. A new role of the Fc-portion of IgG. Immunology. 1979; 38:631–640.
   PubMed Web of Science ®Google Scholar
• Moller NP, Steensgaard J. Fc-mediated immune precipitation. II. Analysis of precipitating immune complexes by rate-zonal ultracentrifugation. Immunology. 1979; 38:641–648.
   PubMed Web of Science ®Google Scholar
• Kolenko P, Dohnalek J, Duskova J, Skalova T, Collard R, Hasek J. New insights into intra- and intermolecular interactions of immunoglobulins: Crystal structure of mouse IgG2b-Fc at 2.1-A resolution. Immunology. 2009; 126:378–385.
   PubMed Web of Science ®Google Scholar
• Kaithamana S, Fan JL, Memar O, Li K, Jutto J, Seetharamaiah GS, Prabhakar BS. Relevance of differential immunogenicity of human and mouse recombinant desmoglein-3 for the induction of acantholytic autoantibodies in mice. Clin Exp Immunol. 2003; 132:16–23.
   PubMed Web of Science ®Google Scholar
• Angelini G, Bonamonte D, Lin MS, Lucchese A, Mittelman A, Serpico R, Simone S, Sinha AA, Kanduc D. Characterization of polyclonal antibodies raised against a linear peptide determinant of desmoglein-3. J Exp Ther Oncol. 2005; 5:1–7.
   PubMedGoogle Scholar
• Nishimura H, Strominger JL. Involvement of a tissue-specific autoantibody in skin disorders of murine systemic lupus erythematosus and autoinflammatory diseases. Proc Natl Acad Sci USA. 2006; 103:3292–3297.
   PubMed Web of Science ®Google Scholar
• Amagai M, Tsunoda K, Suzuki H, Nishifuji K, Koyasu S, Nishikawam T. Use of autoantigen-knockout mice in developing an active autoimmune disease model for Pemphigus. J Clin Invest. 2000; 105:625–631.
   PubMed Web of Science ®Google Scholar
• Aoki-Ota M, Tsunoda K, Ota T, Iwasaki T, Koyasu S, Amagai M, Nishikawa T. A mouse model of Pemphigus vulgaris by adoptive transfer of naive splenocytes from desmoglein 3 knockout mice. Br J Dermatol. 2004; 151:346–354.
   PubMed Web of Science ®Google Scholar
• Amagai M. Pemphigus vulgaris and its active disease mouse model. Curr Dir Autoimmun. 2008; 10:167–181.
   PubMedGoogle Scholar
• Holm TL, Markholst H. Confirmation of a disease model of Pemphigus vulgaris: Characterization and correlation between disease parameters in 90 mice. Exp Dermatol. 2010; 19:e158–e165.
   PubMed Web of Science ®Google Scholar
• Ishii K, Harada R, Matsuo I, Shirakata Y, Hashimoto K, Amagai M. In vitro keratinocyte dissociation assay for evaluation of the pathogenicity of anti-desmoglein 3 IgG autoantibodies in Pemphigus vulgaris. J Invest Dermatol. 2005; 124:939–946.
   PubMed Web of Science ®Google Scholar
• Bhol KC, Ahmed AR. Production of non-pathogenic human monoclonal antibodies to desmoglein 3 from Pemphigus vulgaris patient. Autoimmunity. 2002; 35:87–91.
   PubMed Web of Science ®Google Scholar
• Payne AS, Ishii K, Kacir S, Lin C, Li H, Hanakawa Y, Tsunoda K, Amagai M, Stanley JR, Siegel DL. Genetic and functional characterization of human Pemphigus vulgaris monoclonal autoantibodies isolated by phage display. J Clin Invest. 2005; 115:888–899.
   PubMed Web of Science ®Google Scholar
• Shimizu A, Ishiko A, Ota T, Tsunoda K, Amagai M, Nishikawa T. IgG binds to desmoglein 3 in desmosomes and causes a desmosomal split without keratin retraction in a Pemphigus mouse model. J Invest Dermatol. 2004; 122:1145–1153.
   PubMed Web of Science ®Google Scholar
• Shimizu A, Ishiko A, Ota T, Saito H, Oka H, Tsunoda K, Amagai M, Nishikawa T. In vivo ultrastructural localization of the desmoglein 3 adhesive interface to the desmosome mid-line. J Invest Dermatol. 2005; 124:984–989.
   PubMed Web of Science ®Google Scholar
• Lever WF. Pemphigus. Medicine. 1953; 32:2–123.
   Web of Science ®Google Scholar
• Wilgram GF, Caulfield JB, Lever WF. An electron microscopic study of acantholysis in Pemphigus vulgaris. J Invest Dermatol. 1961; 36:373–382.
   PubMed Web of Science ®Google Scholar
• Hu CH, Michel B, Schiltz JR. Epidermal acantholysis induced in vitro by Pemphigus autoantibody. An ultrastructural study. Am J Pathol. 1978; 90:345–361.
   PubMed Web of Science ®Google Scholar
• Barlow Y, Wray D. Ultrastructural alterations associated with in vivo and in vitro bound Pemphigus antibodies in cultured oral epithelial cells. J Oral Pathol Med. 1991; 20:241–244.
   PubMed Web of Science ®Google Scholar
• Diercks GF, Pas HH, Jonkman MF. The ultrastructure of acantholysis in Pemphigus vulgaris. Br J Dermatol. 2009; 160:450–474.
   PubMed Web of Science ®Google Scholar
• Lambert LL, Spriet E, Vandewiele A, Naeyaert J. Desmoglein 1 and 3 IgG auto-antibody titers do not correlate with Pemphigus disease activity in a prospective study. J Invest Dermatol. 2006; 126 Suppl. 1: 11 (Abstract 65).
   PubMedGoogle Scholar
• Abasq C, Mouquet H, Gilbert D, Tron F, Grassi V, Musette P, Joly P. ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of Pemphigus. Arch Dermatol. 2009; 145:529–535.
   PubMedGoogle Scholar
• Akman A, Uzun S, Alpsoy E. Immunopathologic features of Pemphigus in the east Mediterranean region of Turkey: A prospective study. Skinmed. 2010; 8:12–16.
   PubMedGoogle Scholar
• Arin MJ, Engert A, Krieg T, Hunzelmann N. Anti-CD20 monoclonal antibody (rituximab) in the treatment of Pemphigus. Br J Dermatol. 2005; 153:620–625.
   PubMed Web of Science ®Google Scholar
• Kwon EJ, Yamagami J, Nishikawa T, Amagai M. Anti-desmoglein IgG autoantibodies in patients with Pemphigus in remission. J Eur Acad Dermatol Venereol. 2008; 22:1070–1075.
   PubMed Web of Science ®Google Scholar
• Belloni-Fortina A, Faggion D, Pigozzi B, Peserico A, Bordignon M, Baldo V, Alaibac M. Detection of autoantibodies against recombinant desmoglein 1 and 3 molecules in patients with Pemphigus vulgaris: Correlation with disease extent at the time of diagnosis and during follow-up. Clin Dev Immunol. 2009; 2009:187864.
   PubMedGoogle Scholar
• Brandsen R, Frusic-Zlotkin M, Lyubimov H, Yunes F, Michel B, Tamir A, Milner Y, Brenner S. Circulating Pemphigus IgG in families of patients with Pemphigus: Comparison of indirect immunofluorescence, direct immunofluorescence, and immunoblotting. J Am Acad Dermatol. 1997; 36:44–52.
   PubMed Web of Science ®Google Scholar
• Warren SJ, Lin MS, Giudice GJ, Hoffmann RG, Hans-Filho G, Aoki V, Rivitti EA, Santos V, Diaz LA. The prevalence of antibodies against desmoglein 1 in endemic Pemphigus foliaceus in Brazil. Cooperative Group on Fogo Selvagem Research. N Engl J Med. 2000; 343:23–30.
   PubMed Web of Science ®Google Scholar
• Kricheli D, David M, Frusic-Zlotkin M, Goldsmith D, Rabinov M, Sulkes J, Milner Y. The distribution of Pemphigus vulgaris-IgG subclasses and their reactivity with desmoglein 3 and 1 in Pemphigus patients and their first-degree relatives. Br J Dermatol. 2000; 143:337–342.
   PubMed Web of Science ®Google Scholar
• Torzecka JD, Narbutt J, Sysa-Jedrzejowska A, Waszczykowska E, Lukamowicz J, Pas HH. Detection of Pemphigus autoantibodies by IIF and ELISA tests in patients with Pemphigus vulgaris and foliaceus and in healthy relatives. Med Sci Monit. 2003; 9:CR528–CR533.
   PubMedGoogle Scholar
• Torzecka JD, Wozniak K, Kowalewski C, Waszczykowska E, Sysa-Jedrzejowska A, Pas HH, Narbutt J. Circulating Pemphigus autoantibodies in healthy relatives of Pemphigus patients: Coincidental phenomenon with a risk of disease development?. Arch Dermatol Res. 2007; 299:239–243.
   PubMed Web of Science ®Google Scholar
• Hilario-Vargas J, Dasher DA, Li N, Aoki V, Hans-Filho G, Dos Santos V, Qaqish BF, Rivitti EA, Diaz LA. Prevalence of anti-desmoglein-3 antibodies in endemic regions of Fogo Selvagem in Brazil. J Invest Dermatol. 2006; 126:2044–2048.
   PubMed Web of Science ®Google Scholar
• Ortega Loayza AG, Ramos W, Elgart G, Bouman P, Jimenez G, Avila J, Rojas I, Vilcarromero M, Hurtado J, Lindo G, Galarza C. Antibodies against desmoglein 1 in healthy subjects in endemic and nonendemic areas of Pemphigus foliaceus (fogo selvagem) in Peru. Int J Dermatol. 2006; 45:538–542.
   PubMed Web of Science ®Google Scholar
• Diaz LA, Arteaga LA, Hilario-Vargas J, Valenzuela JG, Li N, Warren S, Aoki V, Hans-Filho G, Eaton D, dos Santos V, Nutman TB, de Mayolo AA, Qaqish BF, Sampaio SA, Rivitti EA. Anti-desmoglein-1 antibodies in onchocerciasis, leishmaniasis and Chagas disease suggest a possible etiological link to Fogo selvagem. J Invest Dermatol. 2004; 123:1045–1051.
   PubMed Web of Science ®Google Scholar
• Yoshimura T, Seishima M, Nakashima K, Yasuhara Y, Adachi S, Kawaguchi M, Minoura N, Nakao T, Kobayashi J, Yamazaki F. Increased antibody levels to desmogleins 1 and 3 after administration of carbamazepine. Clin Exp Dermatol. 2001; 26:441–445.
   PubMed Web of Science ®Google Scholar
• Gallo R, Massone C, Parodi A, Guarrera M. Allergic contact dermatitis from thiurams with Pemphigus-like autoantibodies. Contact Dermatitis. 2002; 46:364–365.
   PubMed Web of Science ®Google Scholar
• Cozzani E, Rosa GM, Drosera M, Intra C, Barsotti A, Parodi A. ACE inhibitors can induce circulating antibodies directed to antigens of the superficial epidermal cells. Arch Dermatol Res. 2010; 303 5: 327–332.
   PubMed Web of Science ®Google Scholar
• Khandpur S, Sharma VK, Sharma A, Pathria G, Satyam A. Comparison of enzyme-linked immunosorbent assay test with immunoblot assay in the diagnosis of Pemphigus in Indian patients. Indian J Dermatol Venereol Leprol. 2010; 76:27–32.
   PubMed Web of Science ®Google Scholar
• Empinotti JC, Aoki V, Filgueira A, Sampaio SA, Rivitti EA, Sanches JAJr, Li N, Hilario-Vargas J, Diaz LA. Clinical and serological follow-up studies of endemic Pemphigus foliaceus (fogo selvagem) in Western Parana, Brazil (2001–2002). Br J Dermatol. 2006; 155:446–450.
   PubMed Web of Science ®Google Scholar
• Bhol K, Mohimen A, Ahmed AR. Correlation of subclasses of IgG with disease activity in Pemphigus vulgaris. Dermatology. 1994; 189 Suppl 1: 85–89.
   PubMed Web of Science ®Google Scholar
• Bhol K, Natarajan K, Nagarwalla N, Mohimen A, Aoki V, Ahmed AR. Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in Pemphigus vulgaris: A model for autoimmunity. Proc Natl Acad Sci USA. 1995; 92:5239–5243.
   PubMed Web of Science ®Google Scholar
• Ayatollahi M, Joubeh S, Mortazavi H, Jefferis R, Ghaderi A. IgG4 as the predominant autoantibody in sera from patients with active state of Pemphigus vulgaris. J Eur Acad Dermatol Venereol. 2004; 18:241–242.
   PubMed Web of Science ®Google Scholar
• Nagel A, Lang A, Engel D, Podstawa E, Hunzelmann N, de Pita O, Borradori L, Uter W, Hertl M. Clinical activity of Pemphigus vulgaris relates to IgE autoantibodies against desmoglein 3. Clin Immunol. 2010; 134:320–330.
   PubMed Web of Science ®Google Scholar
• Mentink LF, de Jong MC, Kloosterhuis GJ, Zuiderveen J, Jonkman MF, Pas HH. Coexistence of IgA antibodies to desmogleins 1 and 3 in Pemphigus vulgaris, Pemphigus foliaceus and paraneoplastic Pemphigus. Br J Dermatol. 2007; 156:635–641.
   PubMed Web of Science ®Google Scholar
• Amagai M, Tsunoda K, Zillikens D, Nagai T, Nishikawa T. The clinical phenotype of Pemphigus is defined by the anti-desmoglein autoantibody profile. J Am Acad Dermatol. 1999; 40:167–170.
   PubMed Web of Science ®Google Scholar
• Arteaga LA, Prisayanh PS, Warren SJ, Liu Z, Diaz LA, Lin MS. A subset of Pemphigus foliaceus patients exhibits pathogenic autoantibodies against both desmoglein-1 and desmoglein-3. J Invest Dermatol. 2002; 118:806–811.
   PubMed Web of Science ®Google Scholar
• Cunha PR, Bystryn JC, Medeiros EP, de Oliveira JR. Sensitivity of indirect immunofluorescence and ELISA in detecting intercellular antibodies in endemic Pemphigus foliaceus (Fogo Selvagem). Int J Dermatol. 2006; 45:914–918.
   PubMed Web of Science ®Google Scholar
• Zagorodniuk I, Weltfriend S, Shtruminger L, Sprecher E, Kogan O, Pollack S, Bergman R. A comparison of anti-desmoglein antibodies and indirect immunofluorescence in the serodiagnosis of Pemphigus vulgaris. Int J Dermatol. 2005; 44:541–544.
   PubMed Web of Science ®Google Scholar
• Sharma VK, Prasad HR, Khandpur S, Kumar A. Evaluation of desmoglein enzyme-linked immunosorbent assay (ELISA) in Indian patients with Pemphigus vulgaris. Int J Dermatol. 2006; 45:518–522.
   PubMed Web of Science ®Google Scholar
• Grando SA, Laquer VT, Le HM. Sirolimus for acute Pemphigus vulgaris: A case report and discussion of dualistic action providing for both immunosuppression and keratinocyte protection. J Am Acad Dermatol. 2011; 65 3: 684–686.
   PubMed Web of Science ®Google Scholar
• Amagai M, Ahmed AR, Kitajima Y, Bystryn JC, Milner Y, Gniadecki R, Hertl M, Pincelli C, Fridkis-Hareli M, Aoyama Y, Frusic-Zlotkin M, Muller E, David M, Mimouni D, Vind-Kezunovic D, Michel B, Mahoney M, Grando S. Are desmoglein autoantibodies essential for the immunopathogenesis of Pemphigus vulgaris, or just “witnesses of disease”?. Exp Dermatol. 2006; 15:815–831.
   PubMed Web of Science ®Google Scholar
• Ohata Y, Amagai M, Ishii K, Hashimoto T. Immunoreactivity against intracellular domains of desmogleins in Pemphigus. J Dermatol Sci. 2001; 25:64–71.
   PubMed Web of Science ®Google Scholar
• Lanza A, Femiano F, De Rosa A, Cammarota M, Lanza M, Cirillo N. The N-terminal fraction of desmoglein 3 encompassing its immunodominant domain is present in human serum: Implications for Pemphigus vulgaris autoimmunity. Int J Immunopathol Pharmacol. 2006; 19:399–407.
   PubMed Web of Science ®Google Scholar
• Dmochowski M, Hashimoto T, Garrod DR, Nishikawa T. Desmocollins I and II are recognized by certain sera from patients with various types of Pemphigus particularly Brazilian Pemphigus foliaceus. J Invest Dermatol. 1993; 100:380–384.
   PubMed Web of Science ®Google Scholar
• Dmochowski M, Hashimoto T, Chidgey MAJ, Yue KKM, Wilkinson RW, Nishikawa T, Garrod DR. Demonstration of antibodies to bovine desmocollin isoforms in certain Pemphigus sera. Br J Dermatol. 1995; 133:519–525.
   PubMed Web of Science ®Google Scholar
• Hisamatsu Y, Amagai M, Garrod DR, Kanzaki T, Hashimoto T. The detection of IgG and IgA autoantibodies to desmocollins 1–3 by enzyme-linked immunosorbent assays using baculovirus-expressed proteins, in atypical Pemphigus but not in typical Pemphigus. Br J Dermatol. 2004; 151:73–83.
   PubMed Web of Science ®Google Scholar
• Muller R, Heber B, Hashimoto T, Messer G, Mullegger R, Niedermeier A, Hertl M. Autoantibodies against desmocollins in European patients with Pemphigus. Clin Exp Dermatol. 2009; 34:898–903.
   PubMed Web of Science ®Google Scholar
• Spindler V, Heupel WM, Efthymiadis A, Schmidt E, Eming R, Rankl C, Hinterdorfer P, Muller T, Drenckhahn D, Waschke J. Desmocollin 3-mediated binding is crucial for keratinocyte cohesion and is impaired in Pemphigus. J Biol Chem. 2009; 284:30556–30564.
   PubMed Web of Science ®Google Scholar
• Mao X, Nagler AR, Farber SA, Choi EJ, Jackson LH, Leiferman KM, Ishii N, Hashimoto T, Amagai M, Zone JJ, Payne AS. Autoimmunity to desmocollin 3 in Pemphigus vulgaris. Am J Pathol. 2010; 177:2724–2730.
   PubMed Web of Science ®Google Scholar
• Grando SA, Dahl MV. Activation of keratinocyte muscarinic acetylcholine receptors reverses Pemphigus acantholysis. J Eur Acad Dermatol Venereol. 1993; 2:72–86.
   Google Scholar
• Grando SA, Horton RM, Pereira EFR, Diethelm-Okita BM, George PM, Albuquerque EX, Conti-Fine BM. A nicotinic acetylcholine receptor regulating cell adhesion and motility is expressed in human keratinocytes. J Invest Dermatol. 1995; 105:774–781.
   PubMed Web of Science ®Google Scholar
• Nguyen VT, Chernyavsky AI, Arredondo J, Bercovich D, Orr-Urtreger A, Vetter DE, Wess J, Beaudet AL, Kitajima Y, Grando SA. Synergistic control of keratinocyte adhesion through muscarinic and nicotinic acetylcholine receptor subtypes. Exp Cell Res. 2004; 294:534–549.
   PubMed Web of Science ®Google Scholar
• Kurzen H, Henrich C, Booken D, Poenitz N, Gratchev A, Klemke CD, Engstner M, Goerdt S, Maas-Szabowski N. Functional characterization of the epidermal cholinergic system in vitro. J Invest Dermatol. 2006; 126:2458–2472.
   PubMed Web of Science ®Google Scholar
• Grando SA. Autoimmunity to keratinocyte acetylcholine receptors in Pemphigus. Dermatology. 2000; 201:290–295.
   PubMed Web of Science ®Google Scholar
• Dick SE, Werth VP. Pemphigus: A treatment update. Autoimmunity. 2006; 39:591–600.
   PubMed Web of Science ®Google Scholar
• Brickman CM, Shoenfeld Y. The mosaic of autoimmunity. Scand J Clin Lab Invest Suppl. 2001; 235:3–15.
   PubMedGoogle Scholar
• Tron F, Gilbert D, Joly P, Mouquet H, Drouot L, Ayed MB, Sellami M, Masmoudi H, Makni S. Immunogenetics of Pemphigus: An update. Autoimmunity. 2006; 39:531–540.
   PubMed Web of Science ®Google Scholar
• Saha M, Harman K, Mortimer NJ, Binda V, Black MM, Kondeatis E, Vaughan R, Groves RW. Pemphigus vulgaris in White Europeans is linked with HLA Class II allele HLA DRB1*1454 but not DRB1*1401. J Invest Dermatol. 2010; 130:311–314.
   PubMed Web of Science ®Google Scholar
• Ahmed AR, Wagner R, Khatri K, Notani G, Awdeh Z, Alper CA, Yunis EJ. Major histocompatibility complex haplotypes and class II genes in non-Jewish patients with Pemphigus vulgaris. Proc Natl Acad Sci USA. 1991; 88:5056–5060.
   PubMed Web of Science ®Google Scholar
• Niizeki H, Inoko H, Narimatsu H, Takata H, Sonoda A, Tadakuma T, Ando A, Tsuji K, Hashimoto T, Nishikawa T. HLA class II antigens are associated with Japanese Pemphigus patients. Hum Immunol. 1991; 31:246–250.
   PubMed Web of Science ®Google Scholar
• Niizeki H, Inoko H, Mizuki N, Inamoto N, Watababe K, Hashimoto T, Nishikawa T. HLA-DQA1, -DQB1 and -DRB1 genotyping in Japanese Pemphigus vulgaris patients by the PCR-RFLP method. Tissue Antigens. 1994; 44:248–251.
   PubMedGoogle Scholar
• Miyagawa S, Amagai M, Niizeki H, Yamashina Y, Kaneshige T, Nishikawa T, Shirai T, Inoko H. HLA-DRB1 polymorphisms and autoimmune responses to desmogleins in Japanese patients with Pemphigus. Tissue Antigens. 1999; 54:333–340.
   PubMedGoogle Scholar
• Hertl M, Karr RW, Amagai M, Katz SI. Heterogeneous MHCII restriction pattern of autoreactive desmoglein 3 specific T cell responses in Pemphigus vulgaris patients and normals. J Invest Dermatol. 1998; 110:388–392.
   PubMed Web of Science ®Google Scholar
• Lin MS, Swartz SJ, Lopez A, Ding X, Fernandez-Vina MA, Stastny P, Fairley JA, Diaz LA. Development and characterization of desmoglein-3 specific T cells from patients with Pemphigus vulgaris. J Clin Invest. 1997; 99:3–40.
   PubMed Web of Science ®Google Scholar
• Riechers R, Grotzinger J, Hertl M. HLA class II restriction of autoreactive T cell responses in Pemphigus vulgaris: Review of the literature and potential applications for the development of a specific immunotherapy. Autoimmunity. 1999; 30:183–196.
   PubMed Web of Science ®Google Scholar
• Veldman C, Stauber A, Wassmuth R, Uter W, Schuler G, Hertl M. Dichotomy of autoreactive Th1 and Th2 cell responses to desmoglein 3 in patients with Pemphigus vulgaris (PV) and healthy carriers of PV-associated HLA class II alleles. J Immunol. 2003; 170:635–642.
   PubMed Web of Science ®Google Scholar
• Nishifuji K, Amagai M, Kuwana M, Iwasaki T, Nishikawa T. Detection of antigen-specific B cells in patients with Pemphigus vulgaris by enzyme-linked immunospot assay: Requirement of T cell collaboration for autoantibody production. J Invest Dermatol. 2000; 114:88–94.
   PubMed Web of Science ®Google Scholar
• Tsunoda K, Ota T, Suzuki H, Ohyama M, Nagai T, Nishikawa T, Amagai M, Koyasu S. Pathogenic autoantibody production requires loss of tolerance against desmoglein 3 in both T and B cells in experimental Pemphigus vulgaris. Eur J Immunol. 2002; 32:627–633.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Amagai M, Nishikawa T, Fujii Y, Kawakami Y, Kuwana M. Novel system evaluating in vivo pathogenicity of desmoglein 3-reactive T cell clones using murine Pemphigus vulgaris. J Immunol. 2008; 181:1526–1535.
   PubMed Web of Science ®Google Scholar
• Aoki-Ota M, Kinoshita M, Ota T, Tsunoda K, Iwasaki T, Tanaka S, Koyasu S, Nishikawa T, Amagai M. Tolerance induction by the blockade of CD40/CD154 interaction in Pemphigus vulgaris mouse model. J Invest Dermatol. 2006; 126:105–113.
   PubMed Web of Science ®Google Scholar
• Hertl M, Amagai M, Sundaram H, Stanley J, Ishii K, Katz SI. Recognition of desmoglein 3 by autoreactive T cells in Pemphigus vulgaris patients and normals. J Invest Dermatol. 1998; 110:62–66.
   PubMed Web of Science ®Google Scholar
• Grando SA, Glukhenky BT, Drannik GN, Kostromin AP, Boiko Y, Senyuk OF. Autoreactive cytotoxic T lymphocytes in Pemphigus and Pemphigoid. Autoimmunity. 1989; 3:247–260.
   PubMed Web of Science ®Google Scholar
• Veldman CM, Gebhard KL, Uter W, Wassmuth R, Grotzinger J, Schultz E, Hertl M. T cell recognition of desmoglein 3 peptides in patients with Pemphigus vulgaris and healthy individuals. J Immunol. 2004; 172:3883–3892.
   PubMed Web of Science ®Google Scholar
• Ahmed AR, Mohimen A, Yunis EJ, Mirza NM, Kumar V, Beutner EH, Alper CA. Linkage of Pemphigus vulgaris antibody to the major histocompatibility complex in healthy relatives of patients. J Exp Med. 1993; 177:419–424.
   PubMed Web of Science ®Google Scholar
• Gebhard KL, Veldman CM, Wassmuth R, Schultz E, Schuler G, Hertl M. Ex vivo analysis of desmoglein 1-responsive T-helper (Th) 1 and Th2 cells in patients with Pemphigus foliaceus and healthy individuals. Exp Dermatol. 2005; 14:586–592.
   PubMed Web of Science ®Google Scholar
• Costantino CM, Baecher-Allan CM, Hafler DA. Human regulatory T cells and autoimmunity. Eur J Immunol. 2008; 38:921–924.
   PubMed Web of Science ®Google Scholar
• Thornton AM, Shevach EM. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol. 2000; 164:183–190.
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Sakaguchi S. Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol. 2006; 16:115–123.
   PubMed Web of Science ®Google Scholar
• Hertl M, Eming R, Veldman C. T cell control in autoimmune bullous skin disorders. J Clin Invest. 2006; 116:1159–1166.
   PubMed Web of Science ®Google Scholar
• Sugiyama H, Matsue H, Nagasaka A, Nakamura Y, Tsukamoto K, Shibagaki N, Kawamura T, Kitamura R, Ando N, Shimada S. CD4+CD25 high regulatory T cells are markedly decreased in blood of patients with Pemphigus vulgaris. Dermatology. 2007; 214:210–220.
   PubMed Web of Science ®Google Scholar
• Veldman C, Hohne A, Dieckmann D, Schuler G, Hertl M. Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with Pemphigus vulgaris. J Immunol. 2004; 172:6468–6475.
   PubMed Web of Science ®Google Scholar
• Arakawa M, Dainichi T, Yasumoto S, Hashimoto T. Lesional Th17 cells in Pemphigus vulgaris and Pemphigus foliaceus. J Dermatol Sci. 2009; 53:228–231.
   PubMed Web of Science ®Google Scholar
• Sebaratnam DF, Martin LK, Rubin AI, Tran K, Pas HH, Marr PJ, Edmonds J, Murrell DF. Reversible relapse of Pemphigus foliaceus triggered by topical imiquimod suggests that Toll-like receptor 7 inhibitors may be useful treatments for Pemphigus. Clin Exp Dermatol. 2011; 36:91–93.
   PubMed Web of Science ®Google Scholar
• Shlomchik MJ. Activating systemic autoimmunity: B's, T's, and tolls. Curr Opin Immunol. 2009; 21:626–633.
   PubMed Web of Science ®Google Scholar
• Amagai M. Autoimmunity against desmosomal cadherins in Pemphigus. J Dermatol Sci. 1999; 20:92–102.
   PubMed Web of Science ®Google Scholar
• Udey MC, Stanley JR. Pemphigus—diseases of antidesmosomal autoimmunity. J Am Med Assoc. 1999; 282:572–576.
   PubMed Web of Science ®Google Scholar
• Karpati S, Amagai M, Prussick R, Cehrs K, Stanley JR. Pemphigus vulgaris antigen, a desmoglein type of cadherin, is localized within keratinocyte desmosomes. J Cell Biol. 1993; 122:409–415.
   PubMed Web of Science ®Google Scholar
• Iwatsuki K, Han GW, Fukuti R, Ohtsuka M, Kikuchi S, Akiba H, Kaneko F. Internalization of constitutive desmogleins with the subsequent induction of desmoglein 2 in Pemphigus lesions. Br J Dermatol. 1999; 140:35–43.
   PubMed Web of Science ®Google Scholar
• Bedane C, Prost C, Thomine E, Intrator L, Joly P, Caux F, Blecker M, Bernard P, Leboutet MJ, Tron F, Lauret P, Bonnetblanc JM, Dubertret L. Binding of autoantibodies is not restricted to desmosomes in Pemphigus vulgaris: Comparison of 14 cases of Pemphigus vulgaris and 10 cases of Pemphigus foliaceus studied by western immunoblot and immunoelectron microscopy. Arch Dermatol Res. 1996; 288:343–352.
   PubMed Web of Science ®Google Scholar
• Waschke J, Bruggeman P, Baumgartner W, Zillikens D, Drenckhahn D. Pemphigus foliaceus IgG causes dissociation of desmoglein 1-containing junctions without blocking desmoglein 1 transinteraction. J Clin Invest. 2005; 115:3157–3165.
   PubMed Web of Science ®Google Scholar
• Muller EJ, Williamson L, Kolly C, Suter MM. Outside-in signaling through integrins and cadherins: A central mechanism to control epidermal growth and differentiation?. J Invest Dermatol. 2008; 128:501–516.
   PubMed Web of Science ®Google Scholar
• Sharma P, Mao X, Payne AS. Beyond steric hindrance: The role of adhesion signaling pathways in the pathogenesis of Pemphigus. J Dermatol Sci. 2007; 48:1–14.
   PubMed Web of Science ®Google Scholar
• Bektas M, Runager K, Petersen JS, Rubenstein DS. Advances in Pemphigus research, signaling, and acantholysis. G Ital Dermatol Venereol. 2010; 145:675–688.
   PubMed Web of Science ®Google Scholar
• Berkowitz P, Hu P, Liu Z, Diaz LA, Enghild JJ, Chua MP, Rubenstein DS. Desmosome signaling: Inhibition of p38MAPK prevents Pemphigus vulgaris IgG induced cytoskeleton reorganization. J Biol Chem. 2005; 280:23778–23784.
   PubMed Web of Science ®Google Scholar
• Rubenstein DS, Diaz LA. Pemphigus antibody induced phosphorylation of keratinocyte proteins. Autoimmunity. 2006; 39:577–586.
   PubMed Web of Science ®Google Scholar
• Lee HE, Berkowitz P, Jolly PS, Diaz LA, Chua MP, Rubenstein DS. Biphasic activation of p38MAPK suggests that apoptosis is a downstream event in Pemphigus acantholysis. J Biol Chem. 2009; 284:12524–12532.
   PubMed Web of Science ®Google Scholar
• Jolly PS, Berkowitz P, Bektas M, Lee HE, Chua M, Diaz LA, Rubenstein DS. p38MAPK signaling and desmoglein-3 internalization are linked events in Pemphigus acantholysis. J Biol Chem. 2010; 285:8936–8941.
   PubMed Web of Science ®Google Scholar
• de Bruin A, Caldelari R, Williamson L, Suter MM, Hunziker T, Wyder M, Muller EJ. Plakoglobin-dependent disruption of the desmosomal plaque in Pemphigus vulgaris. Exp Dermatol. 2007; 16:468–475.
   PubMed Web of Science ®Google Scholar
• Muller EJ, Hunziker T, Suter MM. Keratin intermediate filament retraction is linked to plakoglobin-dependent signaling in Pemphigus vulgaris. J Am Acad Dermatol. 2007; 56:890–891 author reply 891–892.
   PubMed Web of Science ®Google Scholar
• Williamson L, Raess NA, Caldelari R, Zakher A, de Bruin A, Posthaus H, Bolli R, Hunziker T, Suter MM, Muller EJ. Pemphigus vulgaris identifies plakoglobin as key suppressor of c-Myc in the skin. EMBO J. 2006; 25:3298–3309.
   PubMed Web of Science ®Google Scholar
• Caldelari R, de Bruin A, Baumann D, Suter MM, Bierkamp C, Balmer V, Muller E. A central role for the armadillo protein plakoglobin in the autoimmune disease Pemphigus vulgaris. J Cell Biol. 2001; 153:823–834.
   PubMed Web of Science ®Google Scholar
• Calkins CC, Setzer SV, Jennings JM, Summers S, Tsunoda K, Amagai Mq, Kowalczyk AP. Desmoglein endocytosis and desmosome disassembly are coordinated responses to Pemphigus autoantibodies. J Biol Chem. 2006; 281:7623–7634.
   PubMed Web of Science ®Google Scholar
• Delva E, Jennings JM, Calkins CC, Kottke MD, Faundez V, Kowalczyk AP. Pemphigus vulgaris IgG-induced desmoglein-3 endocytosis and desmosomal disassembly are mediated by a clathrin- and dynamin-independent mechanism. J Biol Chem. 2008; 283:18303–18313.
   PubMed Web of Science ®Google Scholar
• Jennings JM, Tucker DK, Kottke MD, Saito M, Delva E, Hanakawa Y, Amagai M, Kowalczyk AP. Desmosome disassembly in response to Pemphigus Vulgaris IgG occurs in distinct phases and can be reversed by expression of exogenous Dsg3. J Invest Dermatol. 2011; 131 3: 706–718.
   PubMed Web of Science ®Google Scholar
• Tsunoda K, Ota T, Aoki M, Yamada T, Nagai T, Nakagawa T, Koyasu S, Nishikawa T, Amagai M. Induction of Pemphigus phenotype by a mouse monoclonal antibody against the amino-terminal adhesive interface of desmoglein 3. J Immunol. 2003; 170:2170–2178.
   PubMed Web of Science ®Google Scholar
• Kawasaki Y, Aoyama Y, Tsunoda K, Amagai M, Kitajima Y. Pathogenic monoclonal antibody against desmoglein 3 augments phosphorylation of desmoglein 3 and p38 MAPK in a human squamous carcinoma cell line. Autoimmunity. 2006; 39:587–590.
   PubMed Web of Science ®Google Scholar
• Nguyen B, Dusek RL, Beaudry VG, Marinkovich MP, Attardi LD. Loss of the desmosomal protein perp enhances the phenotypic effects of Pemphigus vulgaris autoantibodies. J Invest Dermatol. 2009; 129:1710–1718.
   PubMed Web of Science ®Google Scholar
• Sanchez-Carpintero I, Espana A, Pelacho B, Lopez Moratalla N, Rubenstein DS, Diaz LA, Lopez-Zabalza MJ. In vivo blockade of Pemphigus vulgaris acantholysis by inhibition of intracellular signal transduction cascades. Br J Dermatol. 2004; 151:565–570.
   PubMed Web of Science ®Google Scholar
• Frusic-Zlotkin M, Raichenberg D, Wang X, David M, Michel B, Milner Y. Apoptotic mechanism in Pemphigus autoimmunoglobulins-induced acantholysis: Possible involvement of the EGF receptor. Autoimmunity. 2006; 39:563–575.
   PubMed Web of Science ®Google Scholar
• Pretel M, España A, Marquina M, Pelacho B, Lopez-Picazo J, Lopez-Zabalza M. An imbalance in Akt/mTOR is involved in the apoptotic and acantholytic processes in a mouse model of Pemphigus vulgaris. Exp Dermatol. 2009; 18:771–780.
   PubMed Web of Science ®Google Scholar
• Spindler V, Vielmuth F, Schmidt E, Rubenstein DS, Waschke J. Protective endogenous cyclic adenosine 5′-monophosphate signaling triggered by Pemphigus autoantibodies. J Immunol. 2010; 185:6831–6838.
   PubMed Web of Science ®Google Scholar
• Seishima M, Iwasaki-Bessho Y, Itoh Y, Nozawa Y, Amagai M, Kitajima Y. Phosphatidylcholine-specific phospholipase C, but not phospholipase D, is involved in Pemphigus IgG-induced signal transduction. Arch Dermatol Res. 1999; 291:606–613.
   PubMed Web of Science ®Google Scholar
• Cheng H, Kartenbeck J, Kabsch K, Mao X, Marques M, Alonso A. Stress kinase p38 mediates EGFR transactivation by hyperosmolar concentrations of sorbitol. J Cell Physiol. 2002; 192:234–243.
   PubMed Web of Science ®Google Scholar
• Kippenberger S, Bernd A, Loitsch S, Guschel M, Muller J, Bereiter-Hahn J, Kaufmann R. Signaling of mechanical stretch in human keratinocytes via MAP kinases. J Invest Dermatol. 2000; 114:408–412.
   PubMed Web of Science ®Google Scholar
• D'Alessandro M, Russell D, Morley SM, Davies AM, Lane EB. Keratin mutations of epidermolysis bullosa simplex alter the kinetics of stress response to osmotic shock. J Cell Sci. 2002; 115:4341–4351.
   PubMed Web of Science ®Google Scholar
• Schmidt E, Waschke J. Apoptosis in Pemphigus. Autoimmun Rev. 2009; 8:533–537.
   PubMed Web of Science ®Google Scholar
• Mao X, Sano Y, Park JM, Payne AS. p38 mitogen activated protein kinase (MAPK) activation is downstream of the loss of intercellular adhesion in Pemphigus vulgaris. J Biol Chem. 2010; 286 2: 1283–1291.
   PubMed Web of Science ®Google Scholar
• Grando SA, Pittelkow MR, Schallreuter KU. Adrenergic and cholinergic control in the biology of epidermis: Physiological and clinical significance. J Invest Dermatol. 2006; 126:1948–1965.
   PubMed Web of Science ®Google Scholar
• Calautti E, Grossi M, Mammucari C, Aoyama Y, Pirro M, Ono Y, Li J, Dotto GP. Fyn tyrosine kinase is a downstream mediator of Rho/PRK2 function in keratinocyte cell–cell adhesion. J Cell Biol. 2002; 156:137–148.
   PubMed Web of Science ®Google Scholar
• Serres M, Filhol O, Lickert H, Grangeasse C, Chambaz EM, Stappert J, Vincent C, Schmitt D. The disruption of adherens junctions is associated with a decrease of E-cadherin phosphorylation by protein kinase CK2. Exp Cell Res. 2000; 257:255–264.
   PubMed Web of Science ®Google Scholar
• Moon HS, Choi EA, Park HY, Choi JY, Chung HW, Kim JI, Park WI. Expression and tyrosine phosphorylation of E-cadherin, beta- and gamma- catenin, and epidermal growth factor receptor in cervical cancer cells. Gynecol Oncol. 2001; 81:355–359.
   PubMed Web of Science ®Google Scholar
• Hu P, O'Keefe EJ, Rubenstein DS. Tyrosine phosphorylation of human keratinocyte beta-catenin and plakoglobin reversibly regulates their binding to E-cadherin and alpha- catenin. J Invest Dermatol. 2001; 117:1059–1067.
   PubMed Web of Science ®Google Scholar
• Lilien J, Balsamo J, Arregui C, Xu G. Turn-off, drop-out: Functional state switching of cadherins. Dev Dyn. 2002; 224:18–29.
   PubMed Web of Science ®Google Scholar
• Volberg T, Zick Y, Dror R, Sabanay I, Gilon C, Levitzki A, Geiger B. The effect of tyrosine-specific protein phosphorylation on the assembly of adherens-type junctions. EMBO J. 1992; 11:1733–1742.
   PubMed Web of Science ®Google Scholar
• Behrens J, Vakaet L, Friis R, Winterhager E, Van Roy F, Mareel MM, Birchmeier W. Loss of epithelial differentiation and gain of invasiveness correlates with tyrosine phosphorylation of the E-cadherin/beta-catenin complex in cells transformed with a temperature-sensitive v-SRC gene. J Cell Biol. 1993; 120:757–766.
   PubMed Web of Science ®Google Scholar
• Potter MD, Barbero S, Cheresh DA. Tyrosine phosphorylation of VE-cadherin prevents binding of p120- and beta-catenin and maintains the cellular mesenchymal state. J Biol Chem. 2005; 280:31906–31912.
   PubMed Web of Science ®Google Scholar
• Yin T, Getsios S, Caldelari R, Godsel LM, Kowalczyk AP, Muller EJ, Green KJ. Mechanisms of plakoglobin-dependent adhesion: Desmosome-specific functions in assembly and regulation by epidermal growth factor receptor. J Biol Chem. 2005; 280:40355–40363.
   PubMed Web of Science ®Google Scholar
• Amar LS, Shabana AH, Oboeuf M, Martin N, Forest N. Involvement of desmoplakin phosphorylation in the regulation of desmosomes by protein kinase C, in HeLa cells. Cell Adhes Commun. 1999; 7:125–138.
   PubMed Web of Science ®Google Scholar
• Mueller H, Franke WW. Biochemical and immunological characterization of desmoplakins I and II, the major polypeptides of the desmosomal plaque. J Mol Biol. 1983; 163:647–671.
   PubMed Web of Science ®Google Scholar
• Boyer B, Tucker GC, Valles AM, Franke WW, Thiery JP. Rearrangements of desmosomal and cytoskeletal proteins during the transition from epithelial to fibroblastoid organization in cultured rat bladder carcinoma cells. J Cell Biol. 1989; 109:1495–1509.
   PubMed Web of Science ®Google Scholar
• Pasdar M, Li Z, Chan H. Desmosome assembly and disassembly are regulated by reversible protein phosphorylation in cultured epithelial cells. Cell Motil Cytoskeleton. 1995; 30:108–121.
   PubMed Web of Science ®Google Scholar
• Aoyama Y, Owada MK, Kitajima Y. A pathogenic autoantibody. Pemphigus vulgaris-IgG, induces phosphorylation of desmoglein 3, and its dissociation from plakoglobin in cultured keratinocytes. Eur J Immunol. 1999; 29:2233–2240.
   PubMed Web of Science ®Google Scholar
• Aoyama Y, Kitajima Y. Pemphigus vulgaris-IgG causes a rapid depletion of desmoglein 3 (Dsg3) from the triton X-100 soluble pools, leading to the formation of Dsg3-depleted desmosomes in a human squamous carcinoma cell line, DJM-1 cells. J Invest Dermatol. 1999; 112:67–71.
   PubMed Web of Science ®Google Scholar
• Nguyen VT, Arredondo J, Chernyavsky AI, Kitajima Y, Pittelkow M, Grando SA. Pemphigus vulgaris IgG and methylprednisolone exhibit reciprocal effects on keratinocytes. J Biol Chem. 2004; 279:2135–2146.
   PubMed Web of Science ®Google Scholar
• Chernyavsky AI, Arredondo J, Piser T, Karlsson E, Grando SA. Differential coupling of M1 muscarinic and α7 nicotinic receptors to inhibition of Pemphigus acantholysis. J Biol Chem. 2008; 283:3401–3408.
   PubMed Web of Science ®Google Scholar
• Kitajima Y, Inoue S, Yaoita H. Effects of Pemphigus antibody on the organization of microtubules and keratin-intermediate filaments in cultured human keratinocytes. Br J Dermatol. 1986; 114:171–179.
   PubMed Web of Science ®Google Scholar
• Jinbu Y, Kitajima Y, Koto S, Akasaka Y, Yaoita H. Different effects of Pemphigus antibody and plasmin on the distribution of keratin intermediate filaments and desmoplakins between cultured oral and epidermal keratinocytes. J Dermatol Sci. 1992; 3:6–12.
   PubMedGoogle Scholar
• Baroni A, Buommino E, Paoletti I, Orlando M, Ruocco E, Ruocco V. Pemphigus serum and captopril induce heat shock protein 70 and inducible nitric oxide synthase overexpression, triggering apoptosis in human keratinocytes. Br J Dermatol. 2004; 150:1070–1080.
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Lever WF. An electron microscopic study on Pemphigus vulgaris of the mouth and the skin with special reference to the intercellular cement. J Invest Dermatol. 1967; 48:540–552.
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Lever WF. The intercellular cement in Pemphigus vulgaris, an electron microscopic study. Dermatologica. 1967; 135:27–34.
   PubMedGoogle Scholar
• Sams WMJr, Gammon WR. Mechanism of lesion production in Pemphigus and Pemphigoid. J Am Acad Dermatol. 1982; 6:431–452.
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Patel HP, Labib RS, Diaz LA, Anhalt GJ. Experimentally induced Pemphigus vulgaris in neonatal BALB/c mice: A time-course study of clinical, immunologic, ultrastructural, and cytochemical changes. J Invest Dermatol. 1985; 84:41–46.
   PubMed Web of Science ®Google Scholar
• Bystryn J-C, Grando SA. A novel explanation for acantholysis in Pemphigus vulgaris—the “basal cell shrinkage” hypothesis. J Am Acad Dermatol. 2006; 54:513–516.
   PubMed Web of Science ®Google Scholar
• Hotti A, Jarvinen K, Siivola P, Holtta E. Caspases and mitochondria in c-Myc-induced apoptosis: Identification of ATM as a new target of caspases. Oncogene. 2000; 19:2354–2362.
   PubMed Web of Science ®Google Scholar
• Arredondo J, Chernyavsky AI, Karaouni A, Grando SA. Novel mechanisms of target cell death and survival and of therapeutic action of IVIg in Pemphigus. Am J Pathol. 2005; 167:1531–1544.
   PubMed Web of Science ®Google Scholar
• Deb-Basu D, Aleem E, Kaldis P, Felsher DW. CDK2 is required by MYC to induce apoptosis. Cell Cycle. 2006; 5:1342–1347.
   PubMed Web of Science ®Google Scholar
• Lanza A, Cirillo N, Rossiello R, Rienzo M, Cutillo L, Casamassimi A, de Nigris F, Schiano C, Rossiello L, Femiano F, Gombos F, Napoli C. Evidence of key role of Cdk2 overexpression in Pemphigus vulgaris. J Biol Chem. 2008; 283:8736–8745.
   PubMed Web of Science ®Google Scholar
• Gera JF, Mellinghoff IK, Shi Y, Rettig MB, Tran C, Hsu JH, Sawyers CL, Lichtenstein AK. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem. 2004; 279:2737–2746.
   PubMed Web of Science ®Google Scholar
• Gorshtein A, Rubinfeld H, Kendler E, Theodoropoulou M, Cerovac V, Stalla GK, Cohen ZR, Hadani M, Shimon I. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro. Endocr Relat Cancer. 2009; 16:1017–1027.
   PubMed Web of Science ®Google Scholar
• Gniadecki R, Jemec GB, Thomsen BM, Hansen M. Relationship between keratinocyte adhesion and death: Anoikis in acantholytic diseases. Arch Dermatol Res. 1998; 290:528–532.
   PubMed Web of Science ®Google Scholar
• Puviani M, Marconi A, Cozzani E, Pincelli C. Fas ligand in Pemphigus sera induces keratinocyte apoptosis through the activation of caspase-8. J Invest Dermatol. 2003; 120:164–167.
   PubMed Web of Science ®Google Scholar
• Pelacho B, Natal C, Espana A, Sanchez-Carpintero I, Iraburu MJ, Lopez-Zabalza MJ. Pemphigus vulgaris autoantibodies induce apoptosis in HaCaT keratinocytes. FEBS Lett. 2004; 566:6–10.
   PubMed Web of Science ®Google Scholar
• Milner Y, Metezeau P, Kiefer H, Finemesser M, Bregegere F, Zlotkin M, Wang X, Michel B. 1999. Pemphigus an autoimmune disease of the skin: Cell–cell separation versus membrane signaling and apoptosis in acantholysis. In: Shoenfeld Y. editors. The decade of autoimmunityElsevier Science B.V.606–615.
   Google Scholar
• Frusic-Zlotkin M, Pergamentz R, Michel B, David M, Mimouni D, Bregegere F, Milner Y. The interaction of Pemphigus autoimmunoglobulins with epidermal cells: Activation of the fas apoptotic pathway and the use of caspase activity for pathogenicity tests of Pemphigus patients. Ann N Y Acad Sci. 2005; 1050:371–379.
   PubMed Web of Science ®Google Scholar
• Pacheco-Tovar MG, Avalos-Diaz E, Vega-Memije E, Bollain-y-Goytia JJ, Lopez-Robles E, Hojyo-Tomoka MT, Dominguez-Soto L, Herrera-Esparza R. The final destiny of acantholytic cells in Pemphigus is Fas mediated. J Eur Acad Dermatol Venereol. 2009; 23:697–701.
   PubMed Web of Science ®Google Scholar
• Lotti R, Shu E, Truzzi F, Palazzo E, Marconi A, Kitajima Y, Pincelli C. Apoptosis precedes desmoglein cleavage and keratinocyte dissociation in Pemphigus: Anti-Fas Ligand neutralizing antibodies prevent acantholysis both in vitro and in vivo. J Invest Dermatol. 2009; 129 Suppl: S14 (Abstr. #80).
   PubMedGoogle Scholar
• Feliciani C, Toto P, Amerio P, Pour SM, Coscione G, Shivji G, Wang B, Sauder DN. In vitro and in vivo expression of interleukin-1alpha and tumor necrosis factor-alpha mRNA in Pemphigus vulgaris: Interleukin-1alpha and tumor necrosis factor-alpha are involved in acantholysis. J Invest Dermatol. 2000; 114:71–77.
   PubMed Web of Science ®Google Scholar
• Lopez-Robles E, Avalos-Diaz E, Vega-Memije E, Hojyo-Tomoka R, Villalobos S, Fraire L, Domiguez-Soto L, Herrera-Esparza R. TNFalpha and IL-6 are mediators in the blistering process of Pemphigus. Int J Dermatol. 2001; 40:185–188.
   PubMed Web of Science ®Google Scholar
• D'Auria L, Bonifati C, Mussi A, D'Agosto G, De Simone C, Giacalone B, Ferraro C, Ameglio F. Cytokines in the sera of patients with Pemphigus vulgaris: Interleukin-6 and tumour necrosis factor-alpha levels are significantly increased as compared to healthy subjects and correlate with disease activity. Eur Cytokine Netw. 1997; 8:383–387.
   PubMed Web of Science ®Google Scholar
• Ameglio F, D'Auria L, Cordiali-Fei P, Trento E, D'Agosto G, Mastroianni A, Giannetti A, Giacalone B. Anti-intercellular substance antibody log titres are correlated with serum concentrations of interleukin-6, interleukin-15 and tumor necrosis factor-alpha in patients with Pemphigus vulgaris relationships with peripheral blood neutrophil counts, disease severity and duration and patients' age. J Biol Regul Homeost Agents. 1999; 13:220–224.
   PubMed Web of Science ®Google Scholar
• Orlov MD, Chernyavsky AI, Arredondo J, Grando SA. Synergistic actions of Pemphigus vulgaris IgG. Fas-ligand and tumor necrosis factor-alpha during induction of basal cell shrinkage and acantholysis. Autoimmunity. 2006; 39:557–562.
   PubMed Web of Science ®Google Scholar
• Grando SA. Decompensation in proteinase-inhibitor system and application of proteinase inhibitors in Pemphigus and Pemphigoid. J Dermatol Sci. 1992; 4:95–97.
   PubMedGoogle Scholar
• Grando SA, Drannik GN, Glukhenky BT, Kostromin AP, Romanenko AB, Chayun OA, Chernyavsky AI. Clinical and laboratory evaluation of hemocarboadsorption in autoimmune bullous dermatoses. Int J Artif Organs. 1990; 3:181–188.
   Google Scholar
• Keskin DB, Stern JN, Fridkis-Hareli M, Ahmed AR. Cytokine profiles in Pemphigus vulgaris patients treated with intravenous immunoglobulins as compared to conventional immunosuppressive therapy. Cytokine. 2008; 41:315–321.
   PubMed Web of Science ®Google Scholar
• Cirillo N, Lanza M, Femiano F, Gaeta GM, De Rosa A, Gombos F, Lanza A. If Pemphigus vulgaris IgG are the cause of acantholysis, new IgG-independent mechanisms are the concause. J Cell Physiol. 2007; 212:563–567.
   PubMed Web of Science ®Google Scholar
• Wang X, Bregegere F, Frusic-Zlotkin M, Feinmesser M, Michel B, Milner Y. Possible apoptotic mechanism in epidermal cell acantholysis induced by Pemphigus vulgaris autoimmunoglobulins. Apoptosis. 2004; 9:131–143.
   PubMed Web of Science ®Google Scholar
• Wang X, Bregegere F, Soroka Y, Frusic-Zlotkin M, Milner Y. Replicative senescence enhances apoptosis induced by Pemphigus autoimmune antibodies in human keratinocytes. FEBS Lett. 2004; 567:281–286.
   PubMed Web of Science ®Google Scholar
• Grando SA, Glukhenky BT, Drannik GN, Kostromin AP, Chernyavsky AI. Cytotoxic proteases in blister fluid of Pemphigus and Pemphigoid patients. Int J Tissue React. 1989; 11:195–201.
   PubMedGoogle Scholar
• Grando SA, Glukhenky BT, Drannik GN, Epshtein EV, Kostromin AP, Korostash TA. Mediators of inflammation in blister fluids from patients with Pemphigus vulgaris and bullous Pemphigoid. Arch Dermatol. 1989; 125:925–930.
   PubMed Web of Science ®Google Scholar
• Rico MJ, Benning C, Weingart ES, Streilein RD, Hall RPIII. Characterization of skin cytokines in bullous Pemphigoid and Pemphigus vulgaris. Br J Dermatol. 1999; 140:1079–1086.
   PubMed Web of Science ®Google Scholar
• Berkowitz P, Hu P, Warren S, Liu Z, Diaz LA, Rubenstein DS. p38MAPK inhibition prevents disease in Pemphigus vulgaris mice. Proc Natl Acad Sci USA. 2006; 103:12855–12860.
   PubMed Web of Science ®Google Scholar
• Lanza A, Cirillo N. Caspase-dependent cleavage of desmoglein 1 depends on the apoptotic stimulus. Br J Dermatol. 2007; 156:400–402.
   PubMed Web of Science ®Google Scholar
• Cirillo N, Lanza M, De Rosa A, Cammarota M, La Gatta A, Gombos F, Lanza A. The most widespread desmosomal cadherin, desmoglein 2, is a novel target of caspase 3-mediated apoptotic machinery. J Cell Biochem. 2008; 103:598–606.
   PubMed Web of Science ®Google Scholar
• Holubar K, Fellner MJ. 1986. Pemphigus and related diseases. In: Rook A, Parish LC, Beare JM. editors. Practical management of the dermatologic patient. Philadelphia: Lippincott Company153–155.
   Google Scholar
• Muller S, Stanley JR. 1990. Pemphigus: Pemphigus vulgaris and Pemphigus foliaceus. In: Wojnarowska F, Briggaman RA. editors. Management of blistering diseases. London: Chapman and Hall Medical43–61.
   Google Scholar
• Lever WF. 1965. Pemphigus and pemphigoidCharles C. Thomas, Springfield.
   Google Scholar
• Lever WF, Schaumburg-Lever G. Treatment of Pemphigus vulgaris. Results obtained in 84 patients between 1961 and 1982. Arch Dermatol. 1984; 120:44–47.
   PubMedGoogle Scholar
• Murrell DF, Dick S, Ahmed AR, Amagai M, Barnadas MA, Borradori L, Bystryn JC, Cianchini G, Diaz L, Fivenson D, Hall R, Harman KE, Hashimoto T, Hertl M, Hunzelmann N, Iranzo P, Joly P, Jonkman MF, Kitajima Y, Korman NJ, Martin LK, Mimouni D, Pandya AG, Payne AS, Rubenstein D, Shimizu H, Sinha AA, Sirois D, Zillikens D, Werth VP. Consensus statement on definitions of disease, end points, and therapeutic response for Pemphigus. J Am Acad Dermatol. 2008; 58:1043–1046.
   PubMed Web of Science ®Google Scholar
• Grando SA, Grando AA, Glukhenky BT, Doguzov V, Nguyen VT, Holubar K. History and clinical significance of mechanical symptoms in blistering dermatoses: A reappraisal. J Am Acad Dermatol. 2003; 48:86–92.
   PubMed Web of Science ®Google Scholar
• Talbott JH, Lever WF, Consolazio WV. Metabolic studies on patients with Pemphigus. J Invest Dermatol. 1940; 3:31.
   Google Scholar
• Thorn GW, Forsham PH, Frawley TF, Hill SRJr, Roche M, Staehelin D, Wilson DL. Clinical usefulness of ACTH and cortisone. New Eng J Med. 1950; 242:783, 824, 865.
   Web of Science ®Google Scholar
• Risser J, Lewis K, Weinstock MA. Mortality of bullous skin disorders from 1979 through 2002 in the United States. Arch Dermatol. 2009; 145:1005–1008.
   PubMedGoogle Scholar
• Alexandroff AB, Harman KE. Blistering skin disorders: An evidence-based update. Conference report. Br J Dermatol. 2009; 160:502–504.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Westfall AO, Allison J, Bijlsma JW, Freeman A, George V, Kovac SH, Spettell CH, Saag KG. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006; 55:420–426.
   PubMed Web of Science ®Google Scholar
• McDonough AK, Curtis JR, Saag KG. The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol. 2008; 20:131–137.
   PubMed Web of Science ®Google Scholar
• Lever WF, Goldberg HS. Treatment of Pemphigus vulgaris with methotrexate. Arch Dermatol. 1969; 100:70–78.
   PubMedGoogle Scholar
• Wolff K, Schreiner E. Immunosuppressive therapy of Pemphigus vulgaris. Preliminary results of azathioprine (Imuran) treatment (in German). Arch Klin Exp Dermatol. 1969; 235:63–77.
   PubMedGoogle Scholar
• Krain LS, Landau JW, Newcomer VD. Cyclophosphamide in the treatment of Pemphigus vulgaris and bullous Pemphigoid. Arch Dermatol. 1982; 106:657–661.
   Google Scholar
• Piamphongsant T, Ophaswongse S. Treatment of Pemphigus. Int J Dermatol. 1991; 30:139–146.
   PubMed Web of Science ®Google Scholar
• Enk AH, Knop J. Treatment of Pemphigus vulgaris with mycophenolate mofetil. Lancet. 1997; 350:494.
   PubMed Web of Science ®Google Scholar
• Mashkilleyson NA. Heparin action in Pemphigus vulgaris: Clinical and immunologic studies. Acta Derm Venereol. 1985; 65:545–547.
   PubMed Web of Science ®Google Scholar
• Balda BR, Rosenzweig D. Cyclosporin A in the treatment of Pemphigus foliaceus and Pemphigus erythematosus (In German). Hautarzt. 1986; 37:454–457.
   PubMed Web of Science ®Google Scholar
• Knobler RM. Photopheresis—extracorporeal irradiation of 8-MOP containing blood—a new therapeutic modality. Blut. 1987; 54:247–250.
   PubMedGoogle Scholar
• Humbert P, Derancourt C, Aubin F, Agache P. Effects of intravenous gamma-globulin in Pemphigus. J Am Acad Dermatol. 1990; 22:326.
   PubMed Web of Science ®Google Scholar
• Salopek TG, Logsetty S, Tredget EE. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening Pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol. 2002; 47:785–788.
   PubMed Web of Science ®Google Scholar
• Renkl A, Mockenhaupt M, Technau K, Herouy Y, Norgauer J. A novel therapeutic option in Pemphigus vulgaris: Humanized monoclonal anti-CD25 antibody. Br J Dermatol. 2004; 150:1220–1222.
   PubMed Web of Science ®Google Scholar
• Penneys NS, Eaglstein WH, Indgin S, Frost P. Gold sodium thiomalate treatment of Pemphigus. Arch Dermatol. 1973; 108:56–60.
   PubMedGoogle Scholar
• Haim S, Friedman-Birnbaum R. Dapsone in the treatment of Pemphigus vulgaris. Dermatologica. 1978; 156:120–123.
   PubMedGoogle Scholar
• Grando SA. Combined immunosuppressive therapy of autoimmune bullous dermatoses (In Russian). Sov Med. 1988; 2:113–115.
   Google Scholar
• Chaffins ML, Collison D, Fivenson DP. Treatment of Pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: A review of 13 cases. J Am Acad Dermatol. 1993; 28:998–1000.
   PubMed Web of Science ®Google Scholar
• Sawai T, Kitazawa K, Danno K, Sugie T, Machizuki T, Sugiura H, Uehara M. Pemphigus vegetans with oesophageal involvement: Successful treatment with minocycline and nicotinamide. Br J Dermatol. 1995; 132:668–670.
   PubMed Web of Science ®Google Scholar
• Miyamoto H, Takahashi I. Successful treatment of Pemphigus vulgaris with prednisolone and tranilast. Acta Derm Venereol. 1997; 77:87–88.
   PubMed Web of Science ®Google Scholar
• Cunha PR, de Oliveira JR, Salles MR, Jamora J, Bystryn JC. Pemphigus vulgaris with involvement of the cervix treated using thalidomide therapy. Int J Dermatol. 2004; 43:682–684.
   PubMed Web of Science ®Google Scholar
• Ruocco V, Rossi A, Argenziano G, Aatarita C, Alviggi L, Farzati B, Papaleo G. Pathogenicity of the intercellular antibodies of Pemphigus and their periodic removal from the circulation by plasmapheresis. Br J Dermatol. 1978; 98:237–241.
   PubMed Web of Science ®Google Scholar
• Cotterill JA, Barker DJ, Millard LG. Plasma exchange in the treatment of Pemphigus vulgaris. Br J Dermatol. 1978; 98:243.
   PubMed Web of Science ®Google Scholar
• Schmidt E, Klinker E, Opitz A, Herzog S, Sitaru C, Goebeler M, Mansouri Taleghoni B, Brocker EB, Zillikens D. Protein A immunoadsorption: A novel and effective adjuvant treatment of severe Pemphigus. Br J Dermatol. 2003; 148:1222–1229.
   PubMed Web of Science ®Google Scholar
• Satyam A, Khandpur S, Sharma VK, Sharma A. Involvement of T(H)1/T(H)2 cytokines in the pathogenesis of autoimmune skin disease-Pemphigus vulgaris. Immunol Invest. 2000; 38:498–509.
   Google Scholar
• DeKruyff RH, Fang Y, Umetsu DT. Corticosteroids enhance the capacity of macrophages to induce Th2 cytokine synthesis in CD4+ lymphocytes by inhibiting IL-12 production. J Immunol. 1998; 160:2231–2237.
   PubMed Web of Science ®Google Scholar
• Mainali ES, Kikuchi T, Tew JG. Dexamethasone inhibits maturation and alters function of monocyte-derived dendritic cells from cord blood. Pediatr Res. 2005; 58:125–131.
   PubMed Web of Science ®Google Scholar
• Miyaura H, Iwata M. Direct and indirect inhibition of Th1 development by progesterone and glucocorticoids. J Immunol. 2002; 168:1087–1094.
   PubMed Web of Science ®Google Scholar
• Swanson DL, Dahl MV. Methylprednisolone inhibits Pemphigus acantholysis in skin cultures. J Invest Dermatol. 1983; 81:258–260.
   PubMed Web of Science ®Google Scholar
• Jeffes EW, Kaplan RP, Ahmed AR. Acantholysis produced in vitro with Pemphigus serum: Hydrocortisone inhibits acantholysis, while dapsone and 6-mercaptopurine do not inhibit acantholysis. J Clin Lab Immunol. 1984; 4:359–363.
   Google Scholar
• Fine JD, Appell ML, Green LK, Sams WMJr. Pemphigus vulgaris. Combined treatment with intravenous corticosteroid pulse therapy, plasmapheresis, and azathioprine. Arch Dermatol. 1988; 124:236–239.
   PubMed Web of Science ®Google Scholar
• Werth VP. Treatment of Pemphigus vulgaris with brief, high-dose intravenous glucocorticoids. Arch Dermatol. 1996; 132:1435–1439.
   PubMed Web of Science ®Google Scholar
• Roujeau JC. Pulse glucocorticoid therapy. The “big shot” revisited. Arch Dermatol. 1996; 132:1499–1502.
   PubMedGoogle Scholar
• Chryssomallis F, Dimitriades A, Chaidemenos GC, Panagiotides D, Karakatsanis G. Steroid-pulse therapy in Pemphigus vulgaris long term follow-up. Int J Dermatol. 1995; 34:438–442.
   PubMed Web of Science ®Google Scholar
• Saxon A, Stevens RH, Ramer SJ, Clements PJ, Yu DT. Glucocorticoids administered in vivo inhibit human suppressor T lymphocyte function and diminish B lymphocyte responsiveness in in vitro immunoglobulin synthesis. J Clin Invest. 1978; 61:922–930.
   PubMed Web of Science ®Google Scholar
• Aksu D, Peksari Y, Arica IE, Gurgey E. Assessing the autoantibody levels in relation to disease severity and therapy response in Pemphigus patients. Indian J Dermatol. 2010; 55:342–347.
   PubMedGoogle Scholar
• Dumas V, Roujeau JC, Wolkenstein P, Revuz J, Cosnes A. The treatment of mild Pemphigus vulgaris and Pemphigus foliaceus with a topical corticosteroid. Br J Dermatol. 1999; 140:1127–1129.
   PubMed Web of Science ®Google Scholar
• Dobrev H, Popova L, Vlashev D. Proteinase inhibitors and Pemphigus vulgaris. An in vitro and in vivo study. Arch Derm Res. 1996; 288:648–655.
   PubMed Web of Science ®Google Scholar
• Berookhim B, Fischer HD, Weinberg JM. Treatment of recalcitrant Pemphigus vulgaris with the tumor necrosis factor alpha antagonist etanercept. Cutis. 2004; 74:245–247.
   PubMed Web of Science ®Google Scholar
• Lin MH, Hsu CK, Lee JY. Successful treatment of recalcitrant Pemphigus vulgaris and Pemphigus vegetans with etanercept and carbon dioxide laser. Arch Dermatol. 2005; 141:680–682.
   PubMed Web of Science ®Google Scholar
• Shetty A, Marcum CB, Glass LF, Carter JD. Successful treatment of Pemphigus vulgaris with etanercept in four patients. J Drugs Dermatol. 2009; 8:940–943.
   PubMed Web of Science ®Google Scholar
• Pardo J, Mercader P, Mahiques L, Sanchez-Carazo JL, Oliver V, Fortea JM. Infliximab in the management of severe Pemphigus vulgaris. Br J Dermatol. 2005; 153:222–223.
   PubMed Web of Science ®Google Scholar
• Jacobi A, Shuler G, Hertl M. Rapid control of therapy-refractory Pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab. Br J Dermatol. 2005; 153:448–449.
   PubMed Web of Science ®Google Scholar
• Howell SM, Bessinger GT, Altman CE, Belnap CM. Rapid response of IgA Pemphigus of the subcorneal pustular dermatosis subtype to treatment with adalimumab and mycophenolate mofetil. J Am Acad Dermatol. 2005; 53:541–543.
   PubMed Web of Science ®Google Scholar
• Schultz HY, Diaz LA, Sirois DA, Werth VP, Grando SA. Generating Consensus Research Goals and Treatment Strategies for Pemphigus and Pemphigoid: The 2010 JC Bystryn Pemphigus and Pemphigoid Meeting. J Invest Dermatol. 2011; 131 7: 1395–1399.
   PubMed Web of Science ®Google Scholar
• Alpsoy E, Yilmaz E, Basaran E, Yazar S, Cetin L. Is the combination of tetracycline and nicotinamide therapy alone effective in Pemphigus?. Arch Dermatol. 1995; 131:1339–1340.
   PubMedGoogle Scholar
• Hausermann P, Gutersohn T, Beltraminelli H, Schiller P, Buchner SA, Rufli T. [Oral Pemphigus vulgaris. Successful treatment with minocycline and nicotinamide]. Hautarzt. 2002; 53:813–815.
   PubMed Web of Science ®Google Scholar
• Iraji F, Banan L. The efficacy of nicotinamide gel 4% as an adjuvant therapy in the treatment of cutaneous erosions of Pemphigus vulgaris. Dermatol Ther. 2010; 23:308–311.
   PubMed Web of Science ®Google Scholar
• Romanenko AV. The action of nicotinamide on neuromuscular transmission. Fiziologicheskii Zhurnal (Kiev). 1987; 33:51–56.
   PubMedGoogle Scholar
• Koeppen A, Klein J, Erb C, Loeffelholz K. Acetylcholine release and choline availability in rat hippocampus: Effects of exogenous choline and nicotinamide. J Pharmacol Exp Ther. 1997; 282:1139–1145.
   PubMed Web of Science ®Google Scholar
• Stoytcheva M, Zlatev R. Bioelectrocatalytical studies of the effect of some pharmaceuticals on the acetylcholinesterase activity. Electroanalysis. 1996; 8:676–679.
   Web of Science ®Google Scholar
• Mehta JN, Martin AG. A case of Pemphigus vulgaris improved by cigarette smoking. Arch Dermatol. 2000; 136:15–17.
   PubMedGoogle Scholar
• Brenner S, Tur E, Shapiro J, Ruocco V, D'Avino M, Ruocco E, Tsankov N, Vassileva S, Drenovska K, Brezoev P, Barnadas MA, Gonzalez MJ, Anhalt G, Nousari H, Silva MR, Pinto KT, Miranda MF. Pemphigus vulgaris: Environmental factors. Occupational, behavioral, medical, and qualitative food frequency questionnaire. Int J Dermatol. 2001; 40:562–569.
   PubMed Web of Science ®Google Scholar
• Sullivan TP, Elgart GW, Kirsner RS. Pemphigus and smoking. Int J Dermatol. 2002; 41:528–530.
   PubMed Web of Science ®Google Scholar
• Valikhani M, Kavusi S, Chams-Davatchi C, Daneshpazhooh M, Barzegari M, Ghiasi M, Abedini R. Pemphigus and associated environmental factors: A case-control study. Clin Exp Dermatol. 2007; 32:256–260.
   PubMed Web of Science ®Google Scholar
• Valikhani M, Kavusi S, Chams-Davatchi C, Hallaji Z, Esmaili N, Ghandi N, Farahani F, Lajevardi V. Impact of smoking on Pemphigus. Int J Dermatol. 2008; 47:567–570.
   PubMed Web of Science ®Google Scholar
• Morimoto N, Takemoto S, Kawazoe T, Suzuki S. Nicotine at a low concentration promotes wound healing. J Surg Res. 2008; 145:199–204.
   PubMed Web of Science ®Google Scholar
• Arredondo J, Omelchenko DM, Chernyavsky AI, Qian J, Skok M, Grando SA. Functional role of the nicotinic arm of the acetylcholine regulatory axis in human B-cell lines. J Exp Pharmacol. 2009; 1:1–7.
   PubMedGoogle Scholar
• Chernyavsky AI, Arredondo J, Galitovskiy V, Qian J, Grando SA. Structure and function of the nicotinic arm of acetylcholine regulatory axis in human leukemic T cells. Int J Immunopathol Pharmacol. 2009; 22:461–472.
   PubMed Web of Science ®Google Scholar
• Chernyavsky AI, Arredondo J, Skok M, Grando SA. Auto/paracrine control of inflammatory cytokines by acetylcholine in macrophage-like U937 cells through nicotinic receptors. Int Immunopharmacol. 2010; 10:308–315.
   PubMed Web of Science ®Google Scholar
• Wang DW, Zhou RB, Yao YM, Zhu XM, Yin YM, Zhao GJ, Dong N, Sheng ZY. Stimulation of {alpha}7 nicotinic acetylcholine receptor by nicotine increases suppressive capacity of naturally occurring CD4+CD25+ regulatory T cells in mice in vitro. J Pharmacol Exp Ther. 2010; 335:553–561.
   PubMed Web of Science ®Google Scholar
• Qian J, Galitovskiy V, Chernyavsky AI, Marchenko S, Grando SA. Plasticity of the murine spleen T-cell cholinergic receptors and their role in in vitro differentiation of naive CD4 T cells toward the Th1. Th2 and Th17 lineages. Genes Immun. 2011; 12:222–230.
   PubMed Web of Science ®Google Scholar
• Akaike A, Ikeda SR, Brookes N, Pascuzzo GJ, Rickett DL, Albuquerque EX. The nature of the interactions of pyridostigmine with the nicotinic acetylcholine receptor-ionic channel complex. II. Patch clamp studies. Mol Pharmacol. 1984; 25:102–112.
   PubMed Web of Science ®Google Scholar
• Taylor P. 1985. Anticholinesterase agents. In: Gilman AG, Goodman LS, Rall TW, Murad F. editors. Goodman and Gilman's pharmacological basis of therapeutics. New York: Macmillan110–127.
   Google Scholar
• Grando SA, Kist DA, Qi M, Dahl MV. Human keratinocytes synthesize, secrete and degrade acetylcholine. J Invest Dermatol. 1993; 101:32–36.
   PubMed Web of Science ®Google Scholar
• Lanza A, Stellavato A, Heulfe I, Landi C, Gombos F, Cirillo N. Serum of patients with oral Pemphigus vulgaris impairs keratinocyte wound repair in vitro: A time-lapse study on the efficacy of methylprednisolone and pyridostigmine bromide. Oral Dis. 2009; 15:478–483.
   PubMed Web of Science ®Google Scholar
• Nguyen VT, Arredondo J, Chernyavsky AI, Pittelkow MR, Kitajima Y, Grando SA. Pemphigus vulgaris acantholysis ameliorated by cholinergic agonists. Arch Dermatol. 2004; 140:327–334.
   PubMed Web of Science ®Google Scholar
• Grando SA. New approaches to the treatment of Pemphigus. J Invest Dermatol Symp Proc. 2004; 9:84–91.
   PubMedGoogle Scholar
• Nait K, Morioka S, Nakajima S, Ogawa H. Proteinase inhibitors block formation of Pemphigus acantholysis in experimental models of neonatal mice and skin explants: Effects of synthetic and plasma proteinase inhibitors on Pemphigus acantholysis. J Invest Dermatol. 1989; 93:173–177.
   PubMed Web of Science ®Google Scholar
• Iraji F, Yoosefi A. Healing effect of Pilocarpine gel 4% on skin lesions of Pemphigus vulgaris. Int J Dermatol. 2006; 45:743–746.
   PubMed Web of Science ®Google Scholar
• . 1994. The RBI handbook of receptor classificationKebabian JW, Neumeyer JL. Natick: Research Biochemicals International.
   Google Scholar
• Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of Pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006; 355:1772–1779.
   PubMed Web of Science ®Google Scholar
• Morath C, Arns W, Schwenger V, Mehrabi A, Fonouni H, Schmidt J, Zeier M. Sirolimus in renal transplantation. Nephrol Dial Transplant. 2007; 22 Suppl 8: viii61–viii65.
   PubMedGoogle Scholar
• Sehgal SN. Sirolimus: Its discovery, biological properties, and mechanism of action. Transplant Proc. 2003; 35:7S–14S.
   PubMed Web of Science ®Google Scholar
• Luan FL, Hojo M, Maluccio M, Yamaji K, Suthanthiran M. Rapamycin blocks tumor progression: Unlinking immunosuppression from antitumor efficacy. Transplantation. 2002; 73:1565–1572.
   PubMed Web of Science ®Google Scholar
• Liu L, Chen L, Chung J, Huang S. Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins. Oncogene. 2008; 27:4998–5010.
   PubMed Web of Science ®Google Scholar
• Hertl M, Veldman C. T-cellular autoimmunity against desmogleins in Pemphigus, an autoantibody-mediated bullous disorder of the skin. Autoimmun Rev. 2003; 2:278–283.
   PubMed Web of Science ®Google Scholar
• Schumann H, Baetge J, Tasanen K, Wojnarowska F, Schacke H, Zillikens D, Bruckner-Tuderman L. The shed ectodomain of collagen XVII/BP180 is targeted by autoantibodies in different blistering skin diseases. Am J Pathol. 2000; 156:685–695.
   PubMed Web of Science ®Google Scholar
• Simpson A, Levin D, Kazerounian S, Uitto J, Aho S, Mahoney MG. Desmoglein 2 is a new antigenic target of Pemphigus autoantibodies (abstr. #23). J Invest Dermatol. 2001; 117:393.
   Web of Science ®Google Scholar
• Kljuic A, Bazzi H, Sundberg JP, Martinez-Mir A, O'Shaughnessy R, Mahoney MG, Levy M, Montagutelli X, Ahmad W, Aita VM, Gordon D, Uitto J, Whiting D, Ott J, Fischer S, Gilliam TC, Jahoda CA, Morris RJ, Panteleyev AA, Nguyen VT, Christiano AM. Desmoglein 4 in hair follicle differentiation and epidermal adhesion. Evidence from inherited hypotrichosis and acquired Pemphigus vulgaris. Cell. 2003; 113:249–260.
   PubMed Web of Science ®Google Scholar
• Kim SC, Chung YL, Kim J, Cho NJ, Amagai M. Pemphigus vulgaris with autoantibodies to desmoplakin. Br J Dermatol. 2001; 145:838–840.
   PubMed Web of Science ®Google Scholar
• Evangelista F, Dasher DA, Diaz LA, Prisayanh PS, Li N. E-cadherin is an additional immunological target for Pemphigus autoantibodies. J Invest Dermatol. 2008; 128:1710–1718.
   PubMed Web of Science ®Google Scholar
• Korman NJ, Eyre RW, Klaus-Kovtun V, Stanley JR. Demonstration of an adhering-junction molecule (plakoglobin) in the autoantigens of Pemphigus foliaceus and Pemphigus vulgaris. N Engl J Med. 1989; 321:631–635.
   PubMed Web of Science ®Google Scholar
• Lambert J, Bracke S, van Roy F, Pas HH, Bonne S, De Schepper S. Serum plakophilin-3 autoreactivity in paraneoplastic Pemphigus. Br J Dermatol. 2010; 163:630–632.
   PubMed Web of Science ®Google Scholar
• Fiebiger E, Hammerschmid F, Stingl G, Maurer D. Anti-FcεRIα autoantibodies in autoimmune-mediated disorders. Identification of a structure–function relationship. J Clin Invest. 1998; 101:243–251.
   PubMed Web of Science ®Google Scholar
• Grando SA. Pemphigus in the XXI Century: New life to an old story. Autoimmunity. 2006; 39:521–530.
   PubMedGoogle Scholar
• Pitoia F, Moncet D, Glorio R, Graciela Diaz A, Rodriguez Costa G, Carbia S, Cabrera H, Niepomniszcze H. Prevalence of thyroid autoimmunity in patients with Pemphigus vulgaris. Medicina (B Aires). 2005; 65:307–310.
   PubMed Web of Science ®Google Scholar
• Rickman L, Simrak D, Stevens HP, Hunt DM, King IA, Bryant SP, Eady RA, Leigh IM, Arnemann J, Magee AI, Kelsell DP, Buxton RS. N-terminal deletion in a desmosomal cadherin causes the autosomal dominant skin disease striate palmoplantar keratoderma. Hum Mol Genet. 1999; 8:971–976.
   PubMed Web of Science ®Google Scholar
• Baroni A, Buommino E, Ruocco E, Petrazzuolo M, De Filippis A, Satriano RA, Ruocco V, . Captopril modulates acetylcholinesterase in human keratinocytes. Arch Dermatol Res 2011; 303:491–497.
   PubMed Web of Science ®Google Scholar